Search

Pemivibart

Pemivibart (Pemgarda) is a human IgG1 monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain. … [L51733] Due to the amino acid substitutions in the Fc region (M435L/N441A), pemivibart has an extended serum half-life.[L51728]

Eucalyptol

Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant. It controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition. … Eucalyptol is an effective treatment for nonpurulent rhinosinusitis. Eucalyptol reduces inflammation and pain when applied topically. It kills leukaemia cells in vitro.

Ozenoxacin

As of December 11, 2017 the FDA approved Ferrer Internacional S.A.' … s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age

Delandistrogene moxeparvovec

[L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein. … Microdystrophin is a truncated, functional form of dystrophin.

Tranilast

It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. … Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma.

Chloride ion

Lumasiran

[L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1).

Ciclesonide

Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

Insulin lispro

As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin lispro, to lower glucose levels in the blood. … These biochemical changes result in a reduced tendency for self-association resulting in dissolution to a dimer and then to a monomer that is absorbed more rapidly after subcutaneous injection compared

Taletrectinib

[L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … Taletrectinib is an orally available small molecule kinase inhibitor.